A study on the estimation of patients with psoriasis, rheumatoid arthritis and inflammatory bowel diseases as candidates for biological therapies was presented by Luca Degli Esposti of CliCon Srl Società Benefit Italy at the 18th Biosimilar Medicines Conference which took place in Brussels, Belgium on 6‒7 October 2022.
The aim of the study analysis was to estimate the number of patients with psoriasis (PSO), rheumatoid arthritis (RA), and inflammatory bowel diseases (IBDs) covering Crohn's disease and ulcerative colitis, potentially eligible for biological therapy, in an Italian setting of clinical practice, using real-world data.
Biological therapies and the use of biosimilars have transformed disease control in patients with diseases where traditionally non-biologicals therapies have been used.
The study was based on 11.3% of the Italian population. The integration of administrative flows allowed, in full compliance with privacy regulations, to obtain a representation of the entire clinical history of the patient and not just of individual prescriptions. The healthcare resource used were the beneficiary database, the exemption database, the pharmaceutical database, the hospitalization database and the specialistic test and visit database [1].
The COVID-19 pandemic impacted several segments of the biologicals market, as the savings from biosimilar competition have reached an all-time high, the development of access to biologicals remains challenging, the competitive environment in Europe is changing and ensuring preparedness for future biosimilar opportunity [2].
The following series of three articles indicate the number of patients with PSO, RA, and IBDs who are possibly eligible for biological treatments and are still not receiving those treatments.
Related articles
Therapeutic drug monitoring with infliximab improved disease control
Patient perspectives on biosimilars in a high uptake country
Infliximab biosimilars for IBD patients: experience from Italy
|
LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View the latest headline article: Directrices para la regulación de biológicos, biosimilares y radiofármacos en Brasil Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Ver el último artículo de cabecera: Directrices para la regulación de biológicos, biosimilares y radiofármacos en Brasil !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. Luca Degli Esposti. Estimation of patients with psoriasis, rheumatoid arthritis and inflammatory bowel diseases potentially eligible to biological therapies.18th Biosimilar Medicines Conference. 6‒7 October 2022; Brussels, Belgium.
2. GaBI Online - Generics and Biosimilars Initiative. Impact of biosimilar competition in Europe in 2021 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Dec 12]. Available from: www.gabionline.net/reports/impact-of-biosimilar-competition-in-europe-in-2021
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment